SanegeneBio and Innovent Ink Pact To Develop siRNA Drug | India Pharma Outlook

SanegeneBio and Innovent Ink Pact To Develop siRNA Drug

India Pharma Outlook Team | Friday, 29 December 2023

 India Pharma Outlook Team

Sanegene Bio USA Inc and Innovent Biologics, Inc. have announced a collaborative agreement to co-develop SGB-3908, a siRNA drug candidate targeting angiotensinogen (AGT) for hypertension management. Innovent also receives an exclusive option to license SGB-3908's future development, manufacturing, and commercialization rights.

SGB-3908 is an IND-enabling stage siRNA drug developed based on SanegeneBio's proprietary LEAD (Ligand and Enhancer Assisted Delivery) platform. Under the terms of the agreement, both parties will be jointly responsible for the development of SGB-3908 to certain stage. Innovent will receive an exclusive option to pay different option exercise fees to obtain the exclusive development, manufacturing, and commercialization license of SGB-3908 in different areas worldwide, as per pharmabiz  

Innovent's rich clinical development experience and proven commercialization capability, along with SanegeneBio's cutting-edge RNA technology strength, will be combined with both parties' strengths to accelerate the development and ensure the commercial success of this novel siRNA drug candidate, allowing it to help more hypertension patients as soon as possible.

“SGB-3908 utilizes the company's LEAD platform technology with independent intellectual property rights. Through the modular design of delivery ligands, delivery enhancer, sequence-dependent and position-specific chemical modifications, it can accurately knockdown the mRNA and protein expression levels of disease-causing genes and maintain excellent drug potency and efficacy duration. We are delighted to collaborate with Innovent on this promising asset. Innovent has deep expertise in R&D and extensive experience in clinical development and commercialization, combined with the advanced siRNA drug discovery technology of SanegeneBio, it will help us to unlock the full potential of RNAi technology, accelerate the clinical development and commercialization of our pipeline, and meet the unmet medical needs of the hypertension patients.” said Dr. Weimin Wang, founder and chief executive officer of SanegeneBio

© 2024 India Pharma Outlook. All Rights Reserved.